Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Arvinas Inc(ARVN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARVN
09/28/2026: ARVN (1-star) is currently NOT-A-BUY. Pass it for now.
Arvinas Inc is a clinical-stage biotechnology company that has established a leading position in the emerging field of targeted protein degradation through its proprietary PROTAC platform. The company's main strength lies in its innovative drug discovery engine and key strategic partnerships with major pharmaceutical entities like Pfizer. The primary investment story centers on the potential for its lead drug candidates to transform treatments for complex cancers and neurodegenerative diseases. However, investors must consider the significant risks associated with the high failure rate of clinical trials and the company's current lack of recurring revenue. Arvinas may best suit growth-oriented investors who are willing to accept high volatility in exchange for potential breakthroughs.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Arvinas offers high-growth potential linked to its disruptive protein degradation platform. |
| Momentum investor | Mixed fit | Strong fit while clinical trial signals and partnership news remain positive for stock momentum. |
| Value investor | Weak fit | The company lacks current earnings, making it unsuitable for traditional value metrics. |
| Dividend investor | Weak fit | Arvinas provides no dividend income and is not expected to do so for the foreseeable future. |
| Low-risk investor | Weak fit | Clinical-stage biotech investments carry inherent high risk and volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical data outcomes frequently cause sharp, unpredictable stock price swings. |
| Valuation risk | High | Valuations are speculative, based on future clinical success and long-term market potential. |
| Competition risk (protein degradation platforms) | Medium / high | Numerous well-funded entities are racing to develop competing degradation technologies. |
| Business quality | Medium | While the technology is innovative, the lack of commercialized products limits current business quality metrics. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | High | The company must successfully navigate complex clinical trials and regulatory approval processes. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 0.01% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 489.72M USD | Price to earnings Ratio 29.19 | 1Y Target Price 13.93 |
Price to earnings Ratio 29.19 | 1Y Target Price 13.93 | ||
Volume (30-day avg) 769.8K shares | Beta 1.76 | 52 Weeks Range 6.97 - 14.51 | Updated Date 09/27/2026 |
52 Weeks Range 6.97 - 14.51 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Upfront payments, development milestones, and royalties from partners like Pfizer and Bayer. | Arvinas generates cash by selling rights to its technology to larger pharma firms to fund its own drug development. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 29.19 | Forward PE 17.86 | Enterprise Value -48.58M | Price to Sales(TTM) 1.55 |
Enterprise Value -48.58M | Price to Sales(TTM) 1.55 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA -1.62 | Shares Outstanding 64.52M | Shares Floating 56.81M |
Shares Outstanding 64.52M | Shares Floating 56.81M | ||
Percent Insiders 7.8 | Percent Institutions 83.75 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Arvinas Inc
Exchange NASDAQ | Headquarters New Haven, CT, United States | ||
IPO Launch date 2018-09-27 | CEO, President & Director Dr. Randy Teel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 246 | Website https://www.arvinas.com |
Full time employees 246 | Website https://www.arvinas.com | ||
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.